Medidect India

What Medidect India does

Medidect India, operated as a unit of Millennium Oncology India Private Limited (incorporated 2018, Gurugram), holds exclusive Indian rights to deploy PanTum Detect, a multi-tumor screening blood test developed by German firm Zyagnum AG. The test is built on EDIM (Epitope Detection in Monocytes/Macrophages) technology, a flow cytometry-based assay that detects elevated levels of two intracellular enzyme biomarkers — Apo10/DNaseX (indicating disrupted apoptosis and proliferation) and TKTL1 (indicating anaerobic glucose metabolism / Warburg effect) — inside macrophages that have phagocytosed degenerated tumor cells. Positioned as the first IVD CE-certified universal all-solid-tumor screening blood test, PanTum Detect carries claimed 97.5% sensitivity and 99% specificity, validated across 40 tumor entities and 250,000+ blood samples globally, and has obtained Indian regulatory registration.

The product portfolio centers on PanTum Detect and an integrated Cancer-Scan follow-up program that combines pre-screening with targeted confirmatory diagnostics (PET-CT, MRI, histopathology) for individuals who test positive. Medidect sells tiered preventive oncology programs at ₹499–₹14,999 per participant (CancerRiskScan, Basic, Standard, PanTum Basic, PanTum Standard), supplemented by a broader 600+ test laboratory diagnostics menu (biochemistry, microbiology, histopathology, hematology) and free home sample collection. Revenue is generated on a per-test basis across a hybrid GTM: direct-to-consumer booking via website, mobile app and WhatsApp; corporate health camps; empaneled hospitals, clinics and diagnostic centers in the Connected Cancer Care Network; and prospective embedding into insurance policies and government preventive health schemes.

The company operates with a team of 8 and is led by three co-founders — oncologist Dr. Gurdeep Singh Sethi, healthcare executive Gagandeep Singh Bedi (ex-Philips Healthcare and Fortis Healthcare), and Andreas Klein (Zyagnum board advisor) — supported by Lab Director Dr. Pramod Nath and Market Access Partner Dr. Nirod Kumar Singh. End customers span asymptomatic healthy individuals seeking annual cancer screening, corporate wellness sponsors, insurance partners, empaneled healthcare providers, and charitable/social impact partners funding screenings in India's cancer-belt regions.

Name

Medidect India

Legal name

Millennium Oncology India Private Limited

Website

https://medidect.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Medidect India, a unit of Millennium Oncology India Private Limited, exclusively licenses Zyagnum AG's EDIM-based PanTum Detect blood test to screen asymptomatic individuals for all solid tumors. It sells tiered screening programs to consumers, corporates, insurers, and empaneled healthcare providers across India.

Ownership category

akta.pro rank

Product category

Preventive Oncology / Multi-Cancer Screening Services

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)

akta.pro secondary industries

Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Clinical Chemistry & Immunoassay Laboratories (HLAFAMAB)

Keywords

• Multi-cancer screening
• Preventive oncology
• Blood-based diagnostics
• Tumor biomarker testing
• Early cancer detection

Headquarters

HQ city

Gurugram

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. PanTum Detect Blood Test (Individual): Medidect India charges individual consumers for the PanTum Detect blood test and associated Preventive Oncology Programs. The company offers multiple program tiers (CancerRiskScan, Basic, Standard, PanTum Basic, PanTum Standard) at price points ranging from ₹499 to ₹14,999 per participant. Revenue is generated per-test with additional teleconsultation and pathology services bundled into higher-tier programs.
2. Corporate / Group Cancer Protection Programs: Medidect India generates revenue by enrolling corporates, insurers, and government entities as financial sponsors who fund group cancer protection programs for employees, policyholders, or beneficiaries. Programs are offered at per-participant pricing tiers.
3. Healthcare Provider Network (Lab Diagnostics): Medidect India offers a broader menu of laboratory diagnostic services (600+ tests including biochemistry, microbiology, hematology, histopathology) through empaneled healthcare providers and its own lab infrastructure. These services include routine and advanced hematology testing, providing additional revenue streams alongside the core PanTum Detect product.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels7 records

Core offering

Medidect India sells the PanTum Detect blood test, an IVD CE-certified multi-tumor screening assay that uses flow cytometry-based EDIM technology to detect two enzyme biomarkers (Apo10/DNaseX and TKTL1) in macrophages, screening asymptomatic healthy individuals for indications of solid organ cancers. The test is bundled in tiered Cancer Protection Programs priced from ₹499 to ₹14,999 per participant, paired with the Cancer-Scan follow-up diagnostics program for confirmatory imaging and pathology when results are positive. The company also offers a broader menu of laboratory diagnostic services (600+ tests including biochemistry, microbiology, histopathology, and hematology) through partner lab infrastructure.

Product overview

Medidect India offers PanTum Detect, a multi-tumor screening blood test as its core product, powered by proprietary EDIM (Epitope Detection in Monocytes) technology. The company provides a tiered preventive oncology program portfolio including CancerRiskScan (₹999), Basic (₹4,999), Standard (₹11,999), PanTum Basic (₹11,999), and PanTum Standard (₹14,999) packages. The Cancer-Scan Program (add-on) combines PanTum Detect screening with confirmatory diagnostics (PET-CT, MRI, Histopathology) for positive cases. Additionally, the company offers laboratory diagnostic services including biochemistry, microbiology, histopathology, hemoglobin tests, and free home sampling. The product ecosystem centers on early cancer detection through blood-based biomarker analysis using Apo10 and TKTL1 enzyme markers detected via flow cytometry in macrophages.

Differentiator

Problem solved

Functional benefit

Products and services

• PanTum Detect IVD CE-certified multi-tumor screening blood test that screens asymptomatic healthy individuals for indications of benign, premalignant, or malignant tumors across all solid organ cancer types using EDIM technology to detect enzyme biomarkers Apo10 and TKTL1 in macrophages, with reported 97.5% sensitivity and 99% specificity.
• Cancer-Scan Program Multi-tumor screening program that justifies further follow-up cancer diagnostics (PET-CT, MRI, Histopathology/FNAC/biopsy) for asymptomatic healthy individuals who test positive with PanTum Detect, providing confirmation of tumors.
• Biochemistry Tests Routine and stat testing, special biochemical tests, metabolic tests, and drug-level monitoring offered as part of the company's broader laboratory diagnostic services.
• Microbiology Tests Bacteriological, mycological, and parasitological analysis including Aerobic and Anaerobic Bacteriology, Mycology, Parasitology, Mycobacteriology, and Virology/STD sections.
• Histopathology Tests Histopathological examination services for cancer diagnosis and tissue analysis offered as part of the company's laboratory diagnostic services.
• Hematology Tests Hemoglobin and broader hematology testing services as part of comprehensive hematological analysis.
• Free Home Sample Collection Sample collection service at the patient's home or office address for convenient testing, supporting PanTum Detect and broader diagnostic test bookings.

Quantifiable outcome

• PanTum Detect achieves 97.5% sensitivity (true positives) and 99% specificity (true negatives) per IVD CE validation study
• +4 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature3 records

Partnerships

Five partnerships are on record, tiered core, major and supporting.

• Zyagnum AG (Germany)coreTechnology or IntegrationMedidect India (a unit of Millennium Oncology India Private Limited) partnered with Zyagnum AG, acquiring exclusive rights to deploy the breakthrough PanTum Detect multi-tumor screening technology in India. Zyagnum AG provides the EDIM technology platform, which has been validated across 40 tumor entities and 250,000+ blood samples globally. This exclusive licensing arrangement is the foundation of Medidect India's entire business.
• Insurance Sector PartnersmajorGTM or Marketing PartnerInsurance companies are targeted as partners to integrate the PanTum Prevention Solution into health insurance policies sold to healthy individuals. Insurance partners provide financial protection in case of a positive PanTum Detect test result. The model is inspired by an existing insurance plan available in Germany through Hanserkur.de/Krebs-scan.
• Empaneled Healthcare Providers (Connected Cancer Care Network)coreChannel Partner/ Reseller/ DistributorReputed healthcare providers (hospitals, clinics, diagnostic centers) are enrolled into Medidect India's Connected Cancer Care Network. They offer PanTum Detect and the Cancer-Scan program, perform blood sample collection, interpret results with empaneled doctors, and guide follow-up diagnostics (PET-CT, MRI, biopsy) for positive cases. Providers also conduct post-market studies to expand risk group coverage.
• Social Impact / Charitable Capital PartnerssupportingStrategic or Co-development PartnerSocial impact partners (NGOs, charitable trusts, impact investors) provide funding to expand testing capacity and infrastructure, and sponsor mass screening camps and post-market studies for economically disadvantaged populations living in India's cancer belt regions.
• Hansemkur.de / Krebs-scan (Germany)supportingTechnology or IntegrationMedidect India references the German Cancer-Scan insurance program (www.Hanserkur.de/Krebs-scan) as an existing model to be replicated in India, where the Cancer-Scan program is already available as part of an insurance plan in Germany.

Scale indicators3 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Zyagnum AG: Zyagnum AG is the German inventor and owner of EDIM technology and PanTum Detect — the exact same product and underlying biomarker platform Medidect India has exclusively licensed for India. It is the closest comparable as the source-licensor and direct counterpart for the same assay technology.
• GRAIL: GRAIL's Galleri test is a multi-cancer early-detection blood test for asymptomatic individuals that screens for multiple solid tumors from a single blood draw — the same core use case as PanTum Detect — making it a directly comparable multi-cancer screening competitor at the global category level.

Broad incumbents

• Dr. Lal PathLabs: Dr. Lal PathLabs is India's largest diagnostics chain offering a broad menu of pathology and preventive health tests. It is a comparable Indian consumer-facing diagnostics business competing for the same asymptomatic wellness-screening wallet as Medidect.
• Foundation Medicine: Foundation Medicine provides comprehensive genomic profiling and liquid biopsy oncology diagnostics. Its broad portfolio of cancer diagnostic tests and biomarker assays overlaps with Medidect's biomarker-driven cancer screening and laboratory diagnostics offering.
• Exact Sciences (Cologuard): Exact Sciences commercializes Cologuard, a flagship non-invasive blood/stool-based cancer screening test. While Cologuard is single-organ (colorectal), Exact Sciences has expanded into multi-cancer screening through its Shield test and oncological diagnostics — overlapping with PanTum Detect's screening and diagnostic franchise.
• Thyrocare Technologies: Thyrocare is a pan-India preventive diagnostics chain offering tiered, low-cost preventive health check packages — a comparable business model to Medidect's ₹499-to-₹14,999 tiered preventive oncology programs and an entrenched incumbent in India's wellness-testing market.
• Metropolis Healthcare: Metropolis Healthcare is one of India's leading diagnostic chains with a broad test menu including cancer diagnostics, histopathology, and preventive wellness packages — directly overlapping with Medidect's lab services and Cancer-Scan follow-up diagnostics pathway.
• Guardant Health: Guardant Health is a leading liquid-biopsy oncology diagnostics company offering blood-based tests for tumor profiling, MRD, and early detection — directly overlapping with Medidect India's EDIM-based blood-based cancer screening product category.
• Apollo Diagnostics: Apollo Diagnostics, part of the Apollo Hospitals ecosystem, is a national Indian diagnostics chain offering preventive health checkups and oncology diagnostics — a comparable channel for asymptomatic cancer screening and a potential network or competitor for Medidect's Connected Cancer Care Network.

Emerging players

• Strand Life Sciences: Strand Life Sciences is an India-based genomics and clinical diagnostics company focused on molecular diagnostics, oncology, and hereditary cancer screening — an emerging local player with adjacent biomarker-based cancer screening and diagnostics offerings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/medidect

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medidect India